

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲 頂 新 耀 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

ELECTION OF MEANS OF RECEIPT AND LANGUAGE OF CORPORATE COMMUNICATIONS

The Company is making arrangements in accordance with Rules 2.07A and 2.07B of the Listing Rules and its Articles of Association for Shareholders to elect to receive all future Corporate Communications (i) in electronic form on the Company's website at www.everestmedicines.com (where they will continue to be published in both English and Chinese) or in printed form and (ii) if Shareholders elect to receive future Corporate Communications in printed form, to elect to receive them in the English language, in the Chinese language or in both languages. The Company is doing this with a view to increase efficiency, save costs and protect the environment.

PROPOSED ARRANGEMENTS

In accordance with Rules 2.07A and 2.07B of the Listing Rules and the Company's Articles of Association, the following arrangements have been made by the Company:

1. The Company has sent a letter to its Shareholders on 21 January 2022 (the "**First Letter**") together with a reply form with a pre-paid mailing label attached for posting within Hong Kong (the "**Reply Form**"). The First Letter and the Reply Form are in English and Chinese. The Reply Form enables Shareholders to elect any one of the following options:

Option 1: to receive all future Corporate Communications in electronic form on the Company's website at www.everestmedicines.com instead of receiving printed copies, and to receive a printed notification letter for the publication of the relevant Corporate Communications on the website of the Company by post; or

Option 2: to receive the printed English version of all future Corporate Communications by post only; or

Option 3: to receive the printed Chinese version of all future Corporate Communications by post only; or

Option 4: to receive both the printed English and Chinese versions of all future Corporate Communications by post.

The First Letter explains that, if the Company does not receive from a Shareholder a duly completed and signed Reply Form (or any other response from a Shareholder indicating that the Shareholder objects to receiving Corporate Communications in electronic form on the Company’s website) on or before 18 February 2022, the Shareholder will be deemed, until the Shareholder informs the Company otherwise by reasonable notice in writing to the Company c/o Hong Kong Share Registrar at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong or by email to everestmedicines.ecom@computershare.com.hk, to have elected to receive all future Corporate Communications in electronic form on the Company’s website instead of receiving them in printed form.

2. With respect to the Shareholders who choose to receive Corporate Communications in printed form, the Company will send Corporate Communications to the Shareholder in the language or languages selected by the Shareholder unless and until the Shareholder informs the Company otherwise by reasonable prior notice in writing to the Company c/o the Hong Kong Share Registrar at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong or by email to everestmedicines.ecom@computershare.com.hk that the Shareholder wishes to receive Corporate Communications in the other (or both) language(s) (as the case may be) or in electronic form on the Company’s website at www.everestmedicines.com.
3. With respect to the Shareholders who choose to receive Corporate Communications in electronic form on the Company’s website, the Company will notify the Shareholder by post when each Corporate Communication is published on the Company’s website. This notification will be sent to the address of the Shareholder which appears in the Company’s register of members maintained by the Hong Kong Share Registrar.
4. When each Corporate Communication is sent by the Company in accordance with the arrangements described above, a letter (the “**Second Letter**”) and a change request form (the “**Change Request Form**”) with a pre-paid mailing label attached for posting within Hong Kong will be attached to or printed in the relevant Corporate Communication. The Second Letter and Change Request Form will be in English and Chinese. By completing and returning the Change Request Form to the Hong Kong Share Registrar, the Shareholder may elect (i) to receive future Corporate Communications in printed form instead of in electronic form on the Company’s website (or in electronic form on the Company’s website instead of in printed form) or (ii) to change the language in which the Shareholder receives Corporate Communications in printed form.

5. Shareholders shall have the right at any time by reasonable prior notice in writing to the Company (send to the Hong Kong Share Registrar at the above address or by email to everestmedicines.ecom@computershare.com.hk) to elect (i) to receive future Corporate Communications in printed form instead of in electronic form on the Company's website (or in electronic form on the Company's website instead of in printed form) or (ii) to change the language in which they receive Corporate Communications in printed form. If any Shareholder who has elected (or is deemed to have elected) to receive Corporate Communications in electronic form on the Company's website for any reason has difficulty in obtaining access to Corporate Communications on the Company's website, the Company will, upon request by the Shareholder, send Corporate Communications to the Shareholder in printed form free of charge.
6. All future Corporate Communications in both English and Chinese and in accessible format will be available on the Company's website at www.everestmedicines.com and the Stock Exchange's website at www.hkexnews.hk.
7. The Company provides a hotline service (Tel: (852) 2862 8688) which is available during business hours (9:00 a.m. to 6:00 p.m., Monday to Friday, excluding Hong Kong public holidays) to enable Shareholders to make enquiries of the Company's arrangements described above.
8. The First Letter and the Second Letter will indicate that English and Chinese versions of all future Corporate Communications will be available in printed form from the Company and the Hong Kong Share Registrar upon request, as well as on the websites of the Company and the Stock Exchange and that the hotline service is being provided as described above.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

“Articles of Association”	the articles of association of the Company currently in force
“Board”	the board of Directors
“Company”	Everest Medicines Limited, an exempted company with limited liability incorporated in the Cayman Islands, the Shares of which are listed on the Main Board of the Stock Exchange
“Corporate Communications”	any document to be issued by the Company to holders of its securities for their information or action as defined under Rule 1.01 of the Listing Rules, including but not limited to: <ol style="list-style-type: none"> (a) the directors' report, its annual accounts together with a copy of the auditor's report and, where applicable, its summary of financial report; (b) the interim report and, where applicable, its summary interim report;

(c) a notice of meeting;

(d) a listing document;

(e) a circular; and

(f) a proxy form

“ Director(s) ”	director(s) of the Company
“ Hong Kong ”	the Hong Kong Special Administrative Region of the People’s Republic of China
“ Hong Kong Share Registrar ”	the Company’s share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong
“ Listing Rules ”	the Rules Governing the Listing of Securities on The Stock Exchange
“ Shareholder(s) ”	holder of the share(s) of the Company
“ Stock Exchange ”	The Stock Exchange of Hong Kong Limited

By order of the Board
Everest Medicines Limited
Wei Fu
Chairman and Executive Director

Hong Kong, 21 January 2022

As at the date of this announcement, the Board comprises Mr. Wei Fu as Chairman and Executive Director, Dr. Kerry Levan Blanchard, Mr. Ian Ying Woo and Mr. Xiaofan Zhang as Executive Directors, Mr. Yubo Gong and Ms. Lan Kang as Non-executive Directors, and Mr. Bo Tan, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.